1h Free Analyst Time
The Advanced Therapy Medicinal Products CDMO Market grew from USD 7.54 billion in 2023 to USD 8.74 billion in 2024. It is expected to continue growing at a CAGR of 17.06%, reaching USD 22.74 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Advanced Therapy Medicinal Products (ATMPs) are highly innovative biopharmaceuticals, comprising gene therapies, cell therapies, and tissue-engineered products designed to treat a range of diseases by addressing their root genetic causes or through the replacement of dysfunctional cells. The necessity for ATMPs is underscored by an increasing demand for personalized medicine, breakthroughs in biotechnology, and a rise in chronic diseases and rare disorders for which conventional treatments have proven inadequate. ATMPs find application across various segments such as oncology, neurology, and orthopedics, with their end-use scope extending predominantly to hospitals, specialty clinics, and research institutions. Key growth influencers in this market include technological advancements in genomics, favorable regulatory reforms, and increasing investment in biotech R&D. The latest opportunities lie in expanding manufacturing capabilities for ATMPs, fostering strategic partnerships for development, and advancing next-generation therapies like CRISPR-mediated gene editing. However, challenges such as high R&D costs, stringent regulatory landscapes, manufacturing complexities, and limited patient access due to high treatment costs are barriers to growth. The best areas for innovation include enhancing manufacturing processes through automation, developing scalable production technologies, and advancing non-viral gene delivery systems. Research on improving cryopreservation and transport technologies for ATMPs is also critical. Additionally, exploring AI and machine learning for process optimization and outcome prediction presents significant opportunities. The nature of the ATMP CDMO market is competitive and rapidly evolving, characterized by a shift towards integrated services offering comprehensive solutions from development through commercialization. To capitalize on growth opportunities, companies should focus on strategic collaborations, foster advancements in manufacturing technologies, and prioritize investments in innovations that address current market challenges, thereby ensuring feasible scalability and enhanced accessibility of ATMPs.
Understanding Market Dynamics in the Advanced Therapy Medicinal Products CDMO Market
The Advanced Therapy Medicinal Products CDMO Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Proliferation in prevalence of rare diseases with growing emergence of novelinfectious diseases
- Rising numbers of clinical trials for development of advanced therapy medicinal products
- Increasing investments in pharmaceutical research and development worldwide
- Market Restraints
- High cost associated with outsourcing ATMP solutions
- Market Opportunities
- Adoption of advanced technologies by advanced therapy medicinalproducts CDMOs
- Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
- Market Challenges
- Stringent governmental rules and regulations for ATMP approvals andcommercialization
Exploring Porter’s Five Forces for the Advanced Therapy Medicinal Products CDMO Market
Porter’s Five Forces framework further strengthens the insights of the Advanced Therapy Medicinal Products CDMO Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Advanced Therapy Medicinal Products CDMO Market
External macro-environmental factors deeply influence the performance of the Advanced Therapy Medicinal Products CDMO Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Advanced Therapy Medicinal Products CDMO Market
The Advanced Therapy Medicinal Products CDMO Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Advanced Therapy Medicinal Products CDMO Market
The Advanced Therapy Medicinal Products CDMO Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Advanced Therapy Medicinal Products CDMO Market
The Advanced Therapy Medicinal Products CDMO Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Advanced Therapy Medicinal Products CDMO Market, highlighting leading vendors and their innovative profiles. These include Abzena, Advanced Therapies, Inc. by WuXi AppTec, AGC Inc., Aldevron, Almac Group, Arranta Bio Holdings, LLC, Bio Elpida, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Inc., Coriolis Pharma Research GmbH, Eurofins Scientific SE, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, and VIVEBIOTECH S.L..Market Segmentation & Coverage
This research report categorizes the Advanced Therapy Medicinal Products CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:- Products
- Cell Therapy
- Gene Therapy
- Tissue Engineered
- Phase
- Phase I
- Phase II
- Phase III
- Phase IV
- Indication
- Cardiology
- Central Nervous System
- Dermatology
- Endocrine, Metabolic, Genetic
- Gastroenterology
- Hematology
- Immunology & Inflammation
- Infectious Disease
- Musculoskeletal
- Oncology
- Ophthalmology
- End-Users
- Academic and Research Institutions
- Biotechnology & Pharmaceutical Companies
- Clinical Research Organizations (CROs)
- Hospitals and Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Advanced Therapy Medicinal Products CDMO Market, by Products
7. Advanced Therapy Medicinal Products CDMO Market, by Phase
8. Advanced Therapy Medicinal Products CDMO Market, by Indication
9. Advanced Therapy Medicinal Products CDMO Market, by End-Users
10. Americas Advanced Therapy Medicinal Products CDMO Market
11. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market
12. Europe, Middle East & Africa Advanced Therapy Medicinal Products CDMO Market
13. Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
The leading players in the Advanced Therapy Medicinal Products CDMO Market, which are profiled in this report, include:- Abzena
- Advanced Therapies, Inc. by WuXi AppTec
- AGC Inc.
- Aldevron
- Almac Group
- Arranta Bio Holdings, LLC
- Bio Elpida
- BlueReg
- Catalent Inc.
- CELONIC Group
- CGT Catapult
- Charles River Laboratories International, Inc.
- Coriolis Pharma Research GmbH
- Eurofins Scientific SE
- FUJIFILM Corporation
- Lonza Group
- Minaris Regenerative Medicine
- Oxford Biomedica PLC
- Patheon by Thermo Fisher Scientific Inc.
- Rentschler Biopharma SE
- REPROCELL Inc.
- RoslinCT
- Samsung Biologics
- VIVEBIOTECH S.L.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 8.74 Billion |
| Forecasted Market Value ( USD | $ 22.74 Billion |
| Compound Annual Growth Rate | 17.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
